An adverse result was observed in the mRNA expression of FZD6 in clinical samples, which was significantly overexpressed in glioma tumor tissues (*p < 0.05, when compared to peri-tumor normal tissues, where n = 16; Figure 6B). This evidence concerns the gene FZD6 and central nervous system cancer.